Cellanyx
As Co-Founder, Dr. Chander developed Cellanyx’s live cell phenotypic technology. He served as founding CEO until Feb. 2019. . Dr. Chander previously conducted academic research in multidrug resistance, distributed networks, and matrix-biology. Dr. Chander combines his background in biophysics with engineering project management, and phenotypic laboratory developed tests (LDT) development. Dr. Chander received his S.B. in Biology from MIT and a Ph.D. from Columbia University.
This person is not in the org chart
This person is not in any offices
Cellanyx
Cellanyx is developing proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and inform clinical decision-making.